Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | AML research at Dana-Farber: updates from Richard Stone

Richard Stone • 14 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Antibodies

Ongoing acute leukemia research at Dana-Farber Cancer Institute, Boston, MA, is discussed here by Richard Stone, MD, at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Prof. Stone highlights immuno-oncology and targeted agents being investigated, including the inhibition of E-selectin.

More from Richard Stone

2:02
ISAL session highlights: targeting CD123, CD47 & TP53 in AML
Richard Stone • 21 Mar 2023
2:31
Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications
Richard Stone • 21 Mar 2023
1:14
The potential of uproleselan in patients with AML
Richard Stone • 21 Mar 2023
1:57
Insights into the treatment of patients with FLT3-mutated AML & the role of maintenance therapy
Richard Stone • 21 Mar 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals